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Background-—This eHealth implementation study aimed to evaluate strategies to promote opportunistic atrial fibrillation (AF)
screening using electronic screening prompts and improve treatment using electronic decision support (EDS) software.
Methods and Results-—An electronic screening prompt appeared whenever an eligible patient’s (aged ≥65 years, no AF
diagnosis) medical record was opened in participating general practices. General practitioners and practice nurses offered
screening using a smartphone ECG, with validated AF algorithm. Guideline-based EDS was provided to assist treatment
decisions. Deidentified data were collected from practices using a data extraction tool. General practices (n=8) across Sydney,
Australia, screened for a median of 6 months. A total of 1805 of 11 476 (16%) eligible patients who attended were screened
(44% men, mean age 75.7 years). Screening identified 19 (1.1%) new cases of AF (mean age, 79 years; mean CHA2DS2-VASc,
3.7; 53% men). General practitioners (n=30) performed 70% of all screenings (range 1–448 patients per general practitioner).
The proportion of patients with AF who had CHA2DS2-VASc ≥2 for men or ≥3 for women prescribed oral anticoagulants was
higher for those diagnosed during the study: 15 of 18 (83%) for screen-detected and 39 of 46 (85%) for clinically detected,
compared with 933 of 1306 (71%) patients diagnosed before the study (P<0.001). The EDS was accessed 111 times for
patients with AF and for 4 of 19 screen-detected patients.
Conclusions-—The eHealth tools showed promise. Adherence to guideline-based oral anticoagulant prescription was significantly
higher in patients diagnosed during the study period, although the EDS was only used in a minority. While the proportion of eligible
patients screened and EDS use was relatively low, further refinements may improve uptake in clinical practice.
Clinical Trial Registration-—URL: www.anzctr.org.au. Unique identifier: ACTRN12616000850471. ( J Am Heart Assoc. 2019;8:
e010959. DOI: 10.1161/JAHA.118.010959.)
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A trial fibrillation (AF) is the most common heart arrhyth-mia worldwide.1 In Australia, the projected prevalence of
AF by 2034 is 600 000.2 The risk of developing AF rapidly
increases with age, exceeding 20% for those 80 years and
older.3 Growing AF prevalence is a significant financial burden
on the Australian healthcare system, contributing to over
60 000 hospitalizations each year4 with an annual cost of
approximately AU$874 million.5
It has been estimated that between 1.4% and 1.6% of the
population 65 years and older have undiagnosed AF,6 which
can often be asymptomatic.7,8 While AF can cause a 5-fold
increase in risk of stroke,9,10 treatment with appropriate oral
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anticoagulant (OAC) therapy can reduce AF-related stroke risk
by 64%.11 Clinical guidelines include strong recommendations
for OAC (including novel OAC) treatment for patients at high
risk for stroke (as estimated by the CHA2DS2-VASc
12 or the
similar “sexless” CHA2DS2-VA score in the recently released
Australian guidelines13). Large gaps between evidence and
practice have been reported, with almost 40% of eligible
patients not taking OACs.14
Opportunistic screening for AF in people 65 years and older
by pulse palpation or ECG rhythm strip is now recommended
by Australian and European guidelines and expert
consensus.12,13,15 Importantly, these guidelines are referring
to single time point opportunistic screening, rather than
extended ECGmonitoring, whichwill findmore brief paroxysmal
AFwith amore benign prognosis. In terms of the risks of screen-
detected AF, it is thought that the prognosis of opportunistic
single time point screening for AF is likely to be similar to
incidentally detected AF in the absence of symptoms.15,16
While screening is recommended in guidelines, it is rarely
performed in practice. According to a recent survey of general
practitioners (GPs) conducted by The Economist, Australian
respondents had opportunistically screened only 11% of
patients 65 years and older in the past fortnight.17
AF screening in general practices is well aligned with their
role in providing ongoing chronic care for large numbers of
older community-dwelling patients. According to a recent
report, over 35% of patient encounters in general practices
were for chronic health issues and those 65 years and older
(at greater risk of AF) accounted for over 30% of the total
number of general practice encounters.18
A screening program ideally needs a system to accurately
identify eligible patients and prompt staff to perform the
screening. In the “opportunistic screening” arm of the SAFE
(Screening for Atrial Fibrillation in the Elderly)6 cluster
randomized trial, both paper and computer “flags” were used
to encourage staff to take patients’ pulse rates during the
consultation. Ideally, an automatic electronic flag or prompt
could broaden uptake.
Importantly, a screening program should include a system
to support evidence-based treatment for patients with
diagnosed AF.15 A range of interventions have been devel-
oped to increase effective prescribing of guideline-recom-
mended OACs in primary care settings, with mixed success.
These include electronic decision support (EDS) tools,19
targeted GP-education programs,20 consultant-led primary
care anticoagulation assessment clinics,21 and patient-
focused education interventions.22
Our pilot studies showed opportunistic AF screening in
general practice to be feasible (including as an adjunct to
influenza vaccination).23,24 However, a number of barriers
were identified, including the lack of remuneration, lack of
time during flu vaccination, the need for a prompt to remind
staff to screen by identifying eligible patients, and gaps in
evidence-based treatment for those identified with AF. This
implementation study aimed to develop and test a suite of
eHealth tools to overcome these barriers and to support
opportunistic AF screening in general practice by nurses and
GPs, including an automated electronic prompt and evidence-
based EDS for OAC prescription integrated with the 2 most
commonly used electronic medical record (EMR) systems in
Australian general practices.
Methods
This implementation study was conducted in a convenience
sample of 8 general practices between November 2016 and
July 2018 in Sydney, Australia. The study was approved by the
University of Sydney’s human research ethics committee
(project number 2014/962) and registered with the Australia
New Zealand Clinical Trial Registry (trial record ACTR
N12616000850471). Practices gave written informed con-
sent, and patients gave oral consent. The data, analytic
methods, and study materials will not be made available to
other researchers for the purpose of reproducing the results
or replicating the procedure as data sharing is not permitted
by our ethics approval committee. Researchers interested in
the data, methods, or analysis can contact the corresponding
author for more information.
eHealth Study Tools
Smartphone ECG
AliveCor KardiaMobile smartphone ECG (iECG) devices were
used for screening. The iECG is a single-lead ECG approved by
Clinical Perspective
What Is New?
• This study demonstrates the feasibility and utility of a
unique suite of automated eHealth tools to support atrial
fibrillation screening in general practice.
• These eHealth tools are integrated with practices’ electronic
medical records and cover all stages of the screening
process: identifying eligible patients, providing a screening
prompt, recording screening results, providing decision
support to clinicians, and including a data extract system for
quality improvement and monitoring.
What Are the Clinical Implications?
• The use of eHealth tools to support all stages of the
screening process is a promising implementation strategy
for atrial fibrillation screening in general practice.
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the Australian Therapeutic Goods Administration as a medical
device, class IIa. The device has a validated, automated
algorithm for detecting AF, providing an immediate provi-
sional diagnosis of either “normal,” “possible AF,” or
“unclassified.”25
Screening prompt
An AF screening app and prompt was developed in collabo-
ration with a third-party software developer (PenCS). The AF
app ran on the provider’s point-of-care hosting platform,
which extracts information from the general practice EMR and
automates data population from the medical record, thus
eliminating the need for manual data entry. The prompt was
iteratively modified throughout the study based on user
feedback. Specifically, the prominence of the prompt was
improved, as initially it was not prominent, and occasionally
was not visible on the point-of-care tool because of early
space limitations.
In the final version, when an eligible patient’s EMR is opened,
a “pop-up” prompt automatically appears for 5 seconds in the
bottom right of the screen to recommend screening for AF. A
small red “1” remains visible beside the app at the top of the
screen (Figure 1). When screening is complete, staff are able to
record the provisional iECG screening result within the AF app
and click the embedded link to add any provisional diagnoses to
the patient’s medical record.
AF EDS software
An AF treatment algorithm was designed in collaboration with
the George Institute, Sydney, Australia and the University of
Sydney, Australia, to bridge gaps between evidence and
practice in AF risk management.26 The algorithm was built as
an additional module of The George Institute’s HealthTracker
software, which provides information on overall cardiovascu-
lar risk and evidence-based cardiovascular decision support.27
HealthTracker is also accessed through the third-party point-
of-care tool.
The AF EDS algorithm was developed based on the 2016
European Society of Cardiology AF guidelines,12 tested, and
clinically validated. The new AF EDS software uses relevant
data extracted from the patient’s EMR to calculate individual
stroke risk scores (CHA2DS2-VASc). The EDS takes into
consideration coexisting cardiac comorbidities and provides
clinicians with evidence-based recommendations regarding
OAC and antiplatelet treatment, taking into consideration
whether AF is present alone or together with vascular disease.
The EDS also includes information on government pharma-
ceutical benefits scheme eligibility for medications, specific to
each patient to support clinical decisions.
Data extraction tool and “clinical audit” data
Deidentified data from practices’ EMRs were collected using
a third-party data extraction tool, using a custom-designed
configuration for deidentified data collection. Data were
available in CSV format, and provided a point-in-time
snapshot of all adult “active” patients of the practice, ie,
patients who had attended at least 3 times in the past
2 years and once in the past 6 months. Data included
demographic and diagnostic information including AF and
CHA₂DS₂-VASc score, medications prescribed, iECG results
as recorded by GPs/nurses (but not the actual iECG
recordings), and number of times the EDS was accessed
for each patient.
Screening Protocol
General practices were recruited and provided practice-level
written informed consent before participation. Practices were
then set up with the electronic tools for the study. Licenses
for the third-party software were provided free to practices by
government Primary Health Networks. Staff were trained in
the use of the electronic study tools, and nurses were offered
an evidence-based AF training session, accredited for contin-
uing professional development points.
Figure 1. eHealth tools to assist atrial fibrillation (AF) screening.
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Eligible patients were those attending the practice to see
the practice nurse or GP and who were 65 years and older,
with no recorded diagnosis of AF, and had not been screened
with the iECG in the past 12 months. Patients unable to
provide consent and those seen by GPs off site (home or
residential aged care) were excluded from the study.
The nurse or GP explained the purpose and process of
iECG screening and obtained oral consent from the patient.
The nurse or GP then recorded the 30-second iECG, visible
in real-time on the smartphone screen, and entered the
automated interpretation into the AF app. For a “normal”
result, no further action was required. For an “unclassified”
result, follow-up was at the GP’s discretion. A 12-lead ECG
was often recommended, depending on the patient’s
history. For a “possible AF” result, further workup and
management was also at the GP’s discretion. A 12-lead
ECG was generally recommended to provide additional
confirmation and to add extra leads. For patients with
confirmed AF, GPs were encouraged to use the EDS system
to assess stroke risk, CHA2DS2-VASc score, and guideline-
recommended medication.
Reimbursement
Each practice was paid AU$1000 to cover IT setup costs plus
AU$10 per patient for the first 500 patients screened. This
amount was intended to reflect potential “real-world” remu-
neration if screening were reimbursed by Medicare. Screening
was free of charge for patients, although usual consultation
fees applied.
Data Collection and Analysis
Deidentified clinical audit data extracts were taken at
baseline, periodically throughout the study, and at comple-
tion. Following each extract, practices received feedback from
researchers including a brief summary of screening numbers/
results. The McNemar test was used to compare whether the
OAC treatment rate was greater or lower for patients
diagnosed before the study period than for patients diagnosed
during the study period (either screen-detected or otherwise-
detected). Two-tailed P values of <0.05 were considered
significant.
A sample size of 8 to 10 practices was chosen to provide a
sufficient cross-section of practices to test implementation of
the eHealth tools.
Study Outcomes
1. Implementation success identified through process mea-
sures including fidelity to the protocol, and utilization of
eHealth tools.
2. The proportion of eligible people attending the practice
during the study period who were screened.
3. The proportion of people with new AF detected through
screening.
4. Determination of guideline-based OAC prescription rates
for both patients with “screen-detected” and “otherwise-
detected” AF during the study period, compared with the
OAC prescription rates before study commencement.
Results
Nine general practices across Sydney, Australia, were
recruited and 1 practice withdrew before commencing
screening. The screening period was determined by each
practice and ranged from 2 to 12 months (median 6 months).
Across the 8 practices that completed the intervention,
11 476 eligible active patients 65 years and older attended
during the study. A total of 1805 patients (16% of those
attending; range 4–33% per practice) were screened (44%
men; mean age, 75.7 years) (Figure 2). The automated iECG
results, as entered by GPs/practice nurses into the AF app,
were: 1563 normal (86.6%), 67 possible AF (3.7%), and 175
unclassified (9.7%).
GPs (n=30) performed 70% of all screenings (range, 1–448
screenings per GP; median, 7.5 screenings per GP), with the
remaining 30% performed by nursing staff (n=16; range, 1–82
screenings per nurse [median, 30.5 screenings per nurse]).
Eight GPs accounted for 62% of all screenings, of whom 3 of 8
were from the same practice.
New AF
Of screened patients, 19 (1.1%) newcases of AFwere confirmed
(patient mean age, 78.67.8 years; mean CHA2DS2-VASc,
3.70.9 [53% men]). Of these patients, 18 of 19 (95%) had a
class 1 recommendation for OAC according to European
Society of Cardiology guidelines12 (ie, CHA₂DS₂-VASc score
men ≥2 and women ≥3), and 15 of 18 (83%) were prescribed
OAC therapy.
Guideline-Based Treatment of AF Cases
The proportion of patients treated according to European
Society of Cardiology guidelines significantly improved during
the study period (Table). For patients with AF 65 years and
older with a class 1 OAC recommendation, OAC prescription
increased from 71% (933/1306) for AF diagnosed before the
study to 84% (54/64) for patients diagnosed during the study
(screen-detected and clinically detected) (P<0.001). The EDS
was accessed 111 times for patients with AF, and for only 4 of
19 screen-detected patients.
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Figure 2. Study flowchart. AF indicates atrial fibrillation; GP, general practitioner; iECG,
smartphone lead I ECG. *Oral anticoagulant (OAC) recommendations as per European
Society of Cardiology 2016 guidelines.12
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This study demonstrates the feasibility and utility of a unique
suite of automated eHealth tools to support AF screening in
general practice. We are not aware of any other study with
integrated eHealth tools covering all stages of the screening
process—from identifying eligible patients, providing a prompt
for screening, recording screening results data, providing
decision support to clinicians, and including a custom-designed
data extract system for quality improvement and tracking of the
screening program. Importantly, these tools are integrated with
practices’ EMRs, allowing for real-time analysis of the patient’s
medical data. The screening prompt was iteratively and
gradually modified during the study based on user feedback
and thus improved in reliability and visibility. This approach to
improve the prompt is similar to that taken in a Canadian study
evaluating an EMR toolkit for AF management, which took a
“human factors” approach to iteratively refine a user-centered
quality improvement toolkit.28
Overall, the final version of the prompt showed promise.
The real-time ECG trace and immediate results of the iECG
device made screening quick and efficient. The screening
program identified 1.1% of patients with new AF. Importantly,
guideline-based OAC prescription increased during the study,
from 71% (prestudy) to 83% (screen-detected and otherwise-
detected).
The OAC treatment rate of 83% during our study is
substantially higher than the previously reported rates in
Australia of 60%.29,30 This may be reflective of recent trends
where the treatment gap appears to be closing, with some
European studies reporting higher rates of OAC treatment,
likely the result of the introduction of novel OACs.31–33
Despite this, a proportion of people are still inappropriately
treated, with many still prescribed antiplatelets, and the EDS
can assist with further improving guideline-based treatment
aimed at preventing strokes.34
Engagement in the screening process (and, in particular, the
percentage of eligible patients screened) varied between the
practices, despite all practices using the same eHealth tools. A
small number of GPs and practice nurses were highly engaged,
and many of these came from a single practice. This practice,
along with 2 or 3 others in the study, had 1 or more “champion”
(a GP and/or practice manager) driving the program. The
importance of having both a “project champion” and an
“organizational change champion” (who may be the same
person) to implement and, importantly, maintain quality
improvement programs in general practice has been previously
described.35 It was our experience that practice champions,
together with a team approach that gathers enthusiasm, was
critical to success at the individual practice level.
Use of the customized clinical audit data, together with an
audit and feedback system appeared to increase motivation
and engagement. We believe this could be further improved
through a more automated system for practices to receive
frequent feedback during the study as required. Audit and
feedback systems have been shown to improve clinical
performance by a Cochrane review,36 and are currently under
trial as part of a “toolkit” to improve OAC treatment for AF in
primary care in Canada.37
Limitations and Further Development of eHealth
Tools
The main limitation of the study was the reliability of the third-
party platform at practices, meaning the screening prompt
and EDS apps could not be accessed for periods during the
study, and GPs/nurses were not able to screen patients. The
Table. OAC Treatment of AF Detected Before the Study Versus During the Study




















1346 1306 (97) 933 (71)† 213 (16) 160 (12) 3.9 80.0 53
AF diagnosed
during study
66 64 (97) 54 (85)† 3 (5) 7 (11) 3.8
Screen-detected
AF
19 18 (95) 15 (83) 1 (6) 2 (11) 3.8 78.6 53
Otherwise-detected
AF
47 46 (98) 39 (85) 2 (4) 5 (11) 3.8 79.6 45
AF indicates atrial fibrillation; CHA2DS2-VASc: C, congestive heart failure/left ventricular dysfunction; H, high blood pressure; A2, age older than 75 years; D, diabetes mellitus; S2, stroke/
transient ischemic attack/thromboembolism; V, vascular disease (coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque); A, age 65 to 74 years; Sc, sex
category female.
*Oral anticoagulant (OAC) recommendations as per European Society of Cardiology 2016 guidelines.12
†Between-group difference (P<0.001).
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individual and complex nature of the computer setup at each
practice meant that problems were sometimes difficult to
resolve quickly, and thus screening may have become less
habitual, perhaps persisting after the problem was resolved.
Resolving reliability of the third-party platform, better seam-
less integration with the practice medical software, and more
frequent audit feedback to practices may resolve these issues
and improve uptake.
The EDSwas not accessed for all patients with AF, possibly as
it was in a separate app and platform to the EMR, and some GPs
used alternative sources/websites for calculating risk scores.
Nevertheless, OAC prescription was higher compared with
patients who received a diagnosis previously in the practice.
The practice data that were collected, while detailed, were
limited to “active” patients only, as a result of the design of
the data collection tool. This may have excluded patients in
better health, eg, who did not have chronic conditions
necessitating more frequent GP consultations.
The proportion of iECGs with an “unclassified” interpreta-
tion by the device was almost 10%. This is to be expected
given that the automated algorithm was developed for use by
individual patients, and it cannot report as “normal” condi-
tions such as sinus bradycardia or sinus tachycardia, which
are the usual reasons for the unclassified diagnosis. However,
the number of unclassified results did require extra time for
practice nurses/GPs to follow up. The research team was not
able to see the iECGs, and therefore could not report the
sensitivity and specificity of the device’s automated algorithm.
However, the sensitivity and specificity in this study may be
less than the original validation figures, as this was a “real-
world” study, for which we have previously shown reduced
specificity with sensitivity retained.30
The incidence of new AF identified during the study may be
an underestimate, as some AF diagnoses may not have been
recorded as a condition in the patient’s EMR (eg, if only written
in free text notes) and therefore would not appear in our clinical
audit data. Only “active patients” were included in our clinical
audit data, and some patients with paroxysmal AFmay not have
been identified by a single time point assessment.
Conclusions
Overall, the use of eHeatlh tools to support all stages of the
screening process seem to be a promising implementation
strategy for AF screening in general practice.
The proportion of patients with new AF identified during
the screening period (by screening or otherwise) with
CHA₂DS₂-VASc ≥2 men or ≥3 women who were prescribed
OAC therapy as recommended by European Society of
Cardiology/EDS guidelines was significantly higher than for
those who received a diagnosis before the study, although the
EDS was only used in a minority. While the proportion of
eligible patients screened was relatively low, further refine-
ments to the screening process and electronic tools may
improve uptake. Methods to increase engagement and
increase adoption of screening and use of the tools should
be further investigated. To be effective, eHealth tools need to
influence behavior change, and future studies are required to
provide further insight on key requirements to effect change.
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